All In Biotech

NDA 207174 · Accord Hlthcare

Paricalcitol

Paricalcitol · Intravenous · Vitamin D2 Analog; Vitamin D Analog

Last checked: Nov 19, 2026Latest source record: Oct 17, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Feb 4, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

101

23 Phase 3, 1 recruiting

FAERS reports

1,024

842 serious, 204 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 30, 2024.

Paricalcitol Injection is indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. Paricalcitol Injection is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease on dialysis.

Mechanism: Paricalcitol is a synthetic, biologically active vitamin D 2 analog. Preclinical and in vitro studies have demonstrated that paricalcitol's biological actions are mediated through binding of the vitamin D receptor (VDR), which results in the selective activation of vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce PTH levels by inhibiting PTH synthesis and secretion.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • PARICALCITOL · PARICALCITOL 0.01MG/2ML (0.005MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • PARICALCITOL · PARICALCITOL 0.002MG/ML (0.002MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • PARICALCITOL · PARICALCITOL 0.005MG/ML (0.005MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Paricalcitol" as an intervention, any sponsor and status, largest first.

All 101 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • calciphylaxis66
  • death66
  • chronic kidney disease57
  • renal failure56
  • pneumonia54
  • drug ineffective45
  • nausea45
  • sepsis41
  • dyspnoea40
  • end stage renal disease38
  • acute kidney injury37
  • renal impairment37

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200421
20059
20068
200710
200816
200913
201016
201131
201229
201321
201452
201557
201694
2017110
2018127
2019109
2020101
202148
202239
202352
202424
202521
202616

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Paricalcitol* (Paricalcitol)

2024 spending

$3.2M

Beneficiaries

6,465

27,615 claims

Per beneficiary

$491

$2.56 per unit

View as table
YearSpending
2020$4,164,115
2021$3,281,236
2022$4,308,552
2023$4,466,975
2024$3,173,244

Part B: Paricalcitol* (Paricalcitol*) · HCPCS J2501

2024 spending

$670

Beneficiaries

14

19 claims

Per beneficiary

$48

2024 ASP limit $0.79 per unit

View as table
YearSpending
2020$202
2021$234
2022$11
2023$332
2024$670

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 146 on PubMed

Sponsor: Accord Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.